Drug intelligence / Profile preview

V-Boost

Development stage: Phase 2
Lead developer: Immunitor
Modality: Vaccines & Immunotherapeutics
Administration: Oral

Overview

V-Boost is an oral immunotherapeutic vaccine developed by Immunitor LLC for the treatment of glioblastoma multiforme (GBM). It is formulated as a tablet containing hydrolyzed GBM-specific antigens and alloantigens. The vaccine is designed to modulate the patient's immune system to recognize and eliminate GBM tumor cells. It is currently being evaluated in Phase II clinical trials for patients with newly diagnosed or treatment-refractory GBM, including those who have failed standard treatments like surgery, chemotherapy, or radiation.

Beyond the preview

Go deeper on V-Boost.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on V-Boost.

Explore the full profile